Illumina (ILMN) Stock Forecast, Price Target & Predictions
ILMN Stock Forecast
Illumina stock forecast is as follows: an average price target of $200.82 (represents a 55.46% upside from ILMN’s last price of $129.18) and a rating consensus of 'Buy', based on 20 wall street analysts offering a 1-year stock forecast.
ILMN Price Target
The average price target for Illumina (ILMN) is $200.82 based on 1-year price targets from 20 Wall Street analysts in the past 3 months, with a price target range of $562.00 to $58.00. This represents a potential 55.46% upside from ILMN's last price of $129.18.
ILMN Analyst Ratings
According to 20 Wall Street analysts, Illumina's rating consensus is 'Buy'. The analyst rating breakdown for ILMN stock is 0 'Strong Buy' (0.00%), 14 'Buy' (70.00%), 5 'Hold' (25.00%), 1 'Sell' (5.00%), and 0 'Strong Sell' (0.00%).
Illumina Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 28, 2024 | Jasper Hellweg | Argus Research | $150.00 | $131.46 | 14.10% | 16.12% |
| Aug 16, 2024 | Narumi Nakagiri | Daiwa | $154.00 | $130.04 | 18.43% | 19.21% |
| Aug 15, 2024 | Sung Ji Nam | Scotiabank | $164.00 | $127.33 | 28.80% | 26.95% |
| Aug 14, 2024 | Nick Setyan | Wedbush | $58.00 | $123.58 | -53.07% | -55.10% |
| Aug 14, 2024 | Luke Sergott | Barclays | $125.00 | $123.58 | 1.15% | -3.24% |
| Aug 13, 2024 | David Westenberg | Piper Sandler | $195.00 | $124.54 | 56.58% | 50.95% |
| Aug 07, 2024 | Catherine Ramsey Schulte | Robert W. Baird | $124.00 | $125.39 | -1.11% | -4.01% |
| Jul 30, 2024 | Dave Westenberg | Piper Sandler | $200.00 | $122.50 | 63.27% | 54.82% |
| Jun 25, 2024 | Catherine Ramsey Schulte | Robert W. Baird | $119.00 | $110.24 | 7.95% | -7.88% |
| Jun 11, 2024 | Vijay Kumar | Evercore ISI | $175.00 | $110.95 | 57.72% | 35.47% |
The latest Illumina stock forecast, released on Aug 28, 2024 by Jasper Hellweg from Argus Research, set a price target of $150.00, which represents a 14.10% increase from the stock price at the time of the forecast ($131.46), and a 16.12% increase from ILMN last price ($129.18).
Illumina Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 9 | 14 |
| Avg Price Target | $150.00 | $143.22 | $148.86 |
| Last Closing Price | $129.18 | $129.18 | $129.18 |
| Upside/Downside | 16.12% | 10.87% | 15.23% |
In the current month, the average price target of Illumina stock is $150.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 16.12% increase as opposed to Illumina's last price of $129.18. This month's average price target is up 4.73% compared to last quarter, and up 0.77% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 16, 2024 | Benchmark | Buy | Buy | Hold |
| Aug 16, 2024 | Daiwa | - | Buy | Upgrade |
| Aug 15, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Aug 14, 2024 | Goldman Sachs | - | Buy | Upgrade |
| Aug 14, 2024 | Wedbush | Neutral | Outperform | Upgrade |
| Aug 14, 2024 | Barclays | Underweight | Equal-Weight | Upgrade |
| Aug 14, 2024 | Cowen & Co. | Hold | Buy | Upgrade |
| Aug 14, 2024 | Cowen & Co. | Hold | Mixed | Upgrade |
| Aug 14, 2024 | Barclays | Underweight | Hold | Upgrade |
| Aug 13, 2024 | UBS | Buy | Buy | Hold |
Illumina's last stock rating was published by Benchmark on Aug 16, 2024. The company gave ILMN a "Buy" rating, the same as its previous rate.
Illumina Financial Forecast
Illumina Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.12B | - | $1.18B | $1.09B | $1.20B | $1.11B | - | $1.22B | $953.00M | $1.11B | $1.13B | $1.09B | - | $794.00M |
| Avg Forecast | $1.40B | $1.37B | $1.33B | $1.31B | $1.25B | $1.21B | $1.20B | $1.16B | $1.19B | $1.15B | $1.13B | $1.10B | $1.11B | $1.08B | $1.09B | $1.05B | $1.09B | $1.13B | $1.16B | $1.07B | $1.07B | $1.11B | $1.22B | $1.22B | $1.13B | $1.05B | $1.02B | $996.34M | $903.91M | $715.83M |
| High Forecast | $1.40B | $1.37B | $1.34B | $1.32B | $1.26B | $1.22B | $1.20B | $1.17B | $1.19B | $1.15B | $1.14B | $1.10B | $1.12B | $1.09B | $1.10B | $1.06B | $1.12B | $1.15B | $1.17B | $1.07B | $1.08B | $1.12B | $1.22B | $1.26B | $1.16B | $1.08B | $1.05B | $1.03B | $931.28M | $737.50M |
| Low Forecast | $1.39B | $1.36B | $1.33B | $1.31B | $1.24B | $1.21B | $1.19B | $1.15B | $1.18B | $1.14B | $1.12B | $1.09B | $1.10B | $1.07B | $1.09B | $1.04B | $1.07B | $1.10B | $1.15B | $1.06B | $1.07B | $1.10B | $1.22B | $1.19B | $1.10B | $1.02B | $992.10M | $972.96M | $882.70M | $699.03M |
| # Analysts | 5 | 8 | 5 | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 5 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 9 | 10 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | - | 1.01% | 1.02% | 1.12% | 1.00% | - | 1.00% | 0.85% | 1.06% | 1.11% | 1.10% | - | 1.11% |
Illumina's average Quarter revenue forecast for Mar 24 based on 4 analysts is $1.05B, with a low forecast of $1.04B, and a high forecast of $1.06B. ILMN's average Quarter revenue forecast represents a -6.39% decrease compared to the company's last Quarter revenue of $1.12B (Dec 23).
Illumina EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 8 | 5 | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 5 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 9 | 10 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-164.00M | - | $-88.00M | $-64.00M | $41.00M | $4.15B | - | $237.00M | $132.00M | $-545.00M | $187.00M | $193.00M | - | $162.00M |
| Avg Forecast | $421.97M | $413.21M | $403.24M | $397.20M | $377.76M | $366.55M | $361.66M | $350.56M | $359.03M | $346.80M | $341.65M | $331.58M | $335.23M | $326.47M | $330.17M | $232.60M | $328.44M | $341.86M | $350.54M | $211.46M | $323.75M | $455.94M | $369.07M | $192.23M | $103.40M | $414.49M | $170.00M | $300.95M | $328.83M | $184.36M |
| High Forecast | $423.94M | $415.14M | $405.13M | $399.06M | $379.53M | $368.26M | $363.35M | $352.20M | $360.71M | $348.42M | $343.25M | $333.13M | $336.80M | $327.99M | $331.71M | $279.12M | $337.48M | $346.07M | $352.17M | $253.75M | $325.26M | $547.13M | $369.07M | $230.68M | $124.08M | $497.39M | $204.00M | $310.06M | $394.59M | $221.24M |
| Low Forecast | $419.45M | $410.74M | $400.83M | $394.83M | $375.50M | $364.35M | $359.49M | $348.46M | $356.88M | $344.73M | $339.61M | $329.59M | $333.23M | $323.44M | $328.20M | $186.08M | $322.42M | $333.18M | $348.44M | $169.17M | $321.81M | $364.75M | $369.07M | $153.79M | $82.72M | $331.59M | $136.00M | $293.89M | $263.06M | $147.49M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.50% | - | -0.25% | -0.30% | 0.13% | 9.10% | - | 1.23% | 1.28% | -1.31% | 1.10% | 0.64% | - | 0.88% |
6 analysts predict ILMN's average Quarter EBITDA for Mar 23 to be $211.46M, with a high of $253.75M and a low of $169.17M. This is 415.75% upper than Illumina's previous annual EBITDA (Dec 22) of $41.00M.
Illumina Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 8 | 5 | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 5 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 9 | 10 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-176.00M | - | $-234.00M | $3.00M | $112.00M | $-3.82B | - | $86.00M | $257.00M | $317.00M | $185.00M | $147.00M | - | $179.00M |
| Avg Forecast | $262.35M | $254.40M | $236.91M | $246.45M | $199.99M | $192.50M | $187.23M | $190.03M | $190.47M | $178.22M | $166.88M | $159.13M | $149.53M | $138.90M | $17.43M | $84.40M | $2.88M | $23.04M | $2.51M | $76.73M | $40.88M | $289.65M | $96.41M | $69.76M | $61.60M | $263.31M | $115.63M | $220.79M | $231.53M | $120.88M |
| High Forecast | $263.94M | $255.95M | $238.35M | $247.95M | $201.21M | $193.67M | $188.36M | $191.18M | $191.63M | $179.30M | $167.90M | $160.10M | $150.44M | $143.69M | $17.53M | $101.29M | $48.91M | $38.41M | $2.52M | $92.08M | $41.13M | $347.58M | $96.41M | $83.71M | $73.92M | $315.98M | $138.75M | $229.48M | $277.84M | $145.06M |
| Low Forecast | $260.31M | $252.42M | $235.07M | $244.53M | $198.44M | $191.00M | $185.77M | $188.55M | $188.99M | $176.83M | $165.58M | $157.89M | $148.37M | $134.11M | $17.29M | $67.52M | $-23.02M | $-5.76M | $2.49M | $61.38M | $40.56M | $231.72M | $96.41M | $55.80M | $49.28M | $210.65M | $92.50M | $214.05M | $185.23M | $96.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -61.17% | - | -93.39% | 0.04% | 2.74% | -13.17% | - | 1.23% | 4.17% | 1.20% | 1.60% | 0.67% | - | 1.48% |
Illumina's average Quarter net income forecast for Jun 23 is $2.51M, with a range of $2.49M to $2.52M. ILMN's average Quarter net income forecast represents a -16.48% decrease compared to the company's last Quarter net income of $3.00M (Mar 23).
Illumina SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 8 | 5 | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 5 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 9 | 10 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $485.00M | - | $450.00M | $378.00M | $426.00M | $146.00M | - | $308.00M | $298.00M | $879.00M | $413.00M | $374.00M | - | $192.00M |
| Avg Forecast | $447.65M | $438.35M | $427.78M | $421.37M | $400.75M | $388.85M | $383.66M | $371.89M | $380.87M | $367.90M | $362.44M | $351.75M | $355.63M | $346.33M | $350.26M | $302.28M | $348.43M | $362.66M | $371.86M | $274.80M | $343.44M | $803.15M | $391.53M | $249.82M | $234.30M | $730.14M | $258.13M | $319.26M | $268.47M | $129.66M |
| High Forecast | $449.74M | $440.40M | $429.78M | $423.34M | $402.62M | $390.67M | $385.46M | $373.63M | $382.65M | $369.62M | $364.13M | $353.40M | $357.29M | $347.95M | $351.90M | $362.74M | $358.02M | $367.12M | $373.60M | $329.77M | $345.05M | $963.78M | $391.53M | $299.79M | $281.16M | $876.16M | $309.75M | $328.93M | $322.16M | $155.59M |
| Low Forecast | $444.97M | $435.73M | $425.22M | $418.85M | $398.35M | $386.52M | $381.37M | $369.66M | $378.59M | $365.70M | $360.27M | $349.65M | $353.50M | $343.13M | $348.17M | $241.83M | $342.04M | $353.45M | $369.64M | $219.84M | $341.39M | $642.52M | $391.53M | $199.86M | $187.44M | $584.11M | $206.50M | $311.77M | $214.77M | $103.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.39% | - | 1.21% | 1.38% | 1.24% | 0.18% | - | 1.23% | 1.27% | 1.20% | 1.60% | 1.17% | - | 1.48% |
Illumina's average Quarter SG&A projection for Mar 24 is $302.28M, based on 4 Wall Street analysts, with a range of $241.83M to $362.74M. The forecast indicates a -37.67% fall compared to ILMN last annual SG&A of $485.00M (Dec 23).
Illumina EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 8 | 5 | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 5 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 9 | 10 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.11 | - | $-1.48 | $0.02 | $0.71 | $-24.31 | - | $0.55 | $1.76 | $2.09 | $1.27 | $1.01 | - | $1.22 |
| Avg Forecast | $1.65 | $1.60 | $1.49 | $1.55 | $1.26 | $1.21 | $1.18 | $1.20 | $1.20 | $1.12 | $1.05 | $1.00 | $0.94 | $0.87 | $0.11 | $0.04 | $0.02 | $0.14 | $0.02 | $0.01 | $0.26 | $0.28 | $0.61 | $0.90 | $0.46 | $1.32 | $1.36 | $1.39 | $1.11 | $0.81 |
| High Forecast | $1.66 | $1.61 | $1.50 | $1.56 | $1.27 | $1.22 | $1.18 | $1.20 | $1.21 | $1.13 | $1.06 | $1.01 | $0.95 | $0.90 | $0.11 | $0.04 | $0.31 | $0.24 | $0.02 | $0.01 | $0.26 | $0.28 | $0.61 | $0.93 | $0.47 | $1.37 | $1.41 | $1.44 | $1.15 | $0.85 |
| Low Forecast | $1.64 | $1.59 | $1.48 | $1.54 | $1.25 | $1.20 | $1.17 | $1.19 | $1.19 | $1.11 | $1.04 | $0.99 | $0.93 | $0.84 | $0.11 | $0.04 | $-0.14 | $-0.04 | $0.02 | $0.01 | $0.26 | $0.28 | $0.61 | $0.87 | $0.44 | $1.28 | $1.32 | $1.35 | $1.08 | $0.79 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -61.34% | - | -93.92% | 3.71% | 2.76% | -87.39% | - | 0.61% | 3.86% | 1.59% | 0.93% | 0.73% | - | 1.50% |
According to 6 Wall Street analysts, Illumina's projected average Quarter EPS for Jun 23 is $0.02, with a low estimate of $0.02 and a high estimate of $0.02. This represents a -21.21% decrease compared to ILMN previous annual EPS of $0.02 (Mar 23).
Illumina Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ILMN | Illumina | $129.18 | $200.82 | 55.46% | Buy |
| EXAS | Exact Sciences | $65.54 | $96.87 | 47.80% | Buy |
| DHR | Danaher | $274.25 | $313.59 | 14.34% | Buy |
| CDNA | CareDx | $28.87 | $31.00 | 7.38% | Buy |
| TMO | Thermo Fisher Scientific | $611.17 | $646.05 | 5.71% | Buy |
| A | Agilent | $137.31 | $144.90 | 5.53% | Buy |
| WAT | Waters | $325.86 | $325.00 | -0.26% | Buy |
| IDXX | IDEXX Laboratories | $500.55 | $479.75 | -4.16% | Buy |
| NTRA | Natera | $126.51 | $114.38 | -9.59% | Buy |
| TWST | Twist Bioscience | $46.95 | $41.20 | -12.25% | Buy |
ILMN Forecast FAQ
Is Illumina a good buy?
Yes, according to 20 Wall Street analysts, Illumina (ILMN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 70.00% of ILMN's total ratings.
What is ILMN's price target?
Illumina (ILMN) average price target is $200.82 with a range of $58 to $562, implying a 55.46% from its last price of $129.18. The data is based on 20 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Illumina stock go up soon?
According to Wall Street analysts' prediction for ILMN stock, the company can go up by 55.46% (from the last price of $129.18 to the average price target of $200.82), up by 335.05% based on the highest stock price target, and down by -55.10% based on the lowest stock price target.
Can Illumina stock reach $200?
ILMN's average twelve months analyst stock price target of $200.82 supports the claim that Illumina can reach $200 in the near future.
What is Illumina's current price target trend?
1 Wall Street analyst forecast a $150 price target for Illumina (ILMN) this month, up 16.12% from its last price of $129.18. Compared to the last 3 and 12 months, the average price target increased by 10.87% and increased by 15.23%, respectively.
What are Illumina's analysts' financial forecasts?
Illumina's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $4.82B (high $4.84B, low $4.79B), average EBITDA is $1.46B (high $1.46B, low $1.45B), average net income is $769.75M (high $774.43M, low $763.76M), average SG&A $1.55B (high $1.55B, low $1.54B), and average EPS is $4.84 (high $4.87, low $4.8). ILMN's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $5.42B (high $5.44B, low $5.38B), average EBITDA is $1.64B (high $1.64B, low $1.63B), average net income is $1B (high $1.01B, low $992.33M), average SG&A $1.74B (high $1.74B, low $1.72B), and average EPS is $6.29 (high $6.33, low $6.24).
Did the ILMN's actual financial results beat the analysts' financial forecasts?
Based on Illumina's last annual report (Dec 2023), the company's revenue was $4.58B, beating the average analysts forecast of $4.45B by 3.11%. Apple's EBITDA was $4.89B, beating the average prediction of $1.23B by 296.58%. The company's net income was $-4.404B, missing the average estimation of $105.16M by -4287.99%. Apple's SG&A was $1.3B, missing the average forecast of $1.36B by -4.47%. Lastly, the company's EPS was $-28.05, missing the average prediction of $0.184 by -15330.00%. In terms of the last quarterly report (Dec 2023), Illumina's revenue was $1.12B, beating the average analysts' forecast of $1.09B by 3.19%. The company's EBITDA was $-164M, missing the average prediction of $328.44M by -149.93%. Illumina's net income was $-176M, missing the average estimation of $2.88M by -6216.92%. The company's SG&A was $485M, beating the average forecast of $348.43M by 39.20%. Lastly, the company's EPS was $-1.11, missing the average prediction of $0.0181 by -6233.95%